Protocol Ledger

NCT06873945 · Phase III · RECRUITING

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

Interventional Phase III clinical trial protocol NCT06873945 sponsored by Pfizer in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-01 Enrollment: 674 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06873945
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)674 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06873945
Protocol FieldVerified Registry Value
NCT IdentifierNCT06873945
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment674 participants (ESTIMATED)
Registered Start Date2025-04-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI